Form D · Pharmaceuticals
Spectrum Antimicrobials, Inc.
Petaluma, CA · CIK 0001808754
Offering snapshot reported Apr 1, 2026 · SEC filing
- Reported sold
- $26.4M Offering amount: $35M
- Investors reported
- 247 Form D · investor count
- Minimum accepted
- $10K Reported outside-investor minimum
- First sale
- Mar 21, 2020 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
- Reported sold$13,411,475 → $26,385,000
- Reported investors108 → 247
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 1, 2026 | Amendment | $26,385,000 | $12,973,525vs Oct 22, 2024 | 247 | SEC filing |
| Oct 22, 2024 | Amendment | $13,411,475 | $300,000vs Sep 13, 2024 | 108 | SEC filing |
| Sep 16, 2024 | Initial | $3,855,000 | No comparison | 28 | SEC filing |
| Sep 13, 2024 | Amendment | $13,111,475 | $5,451,475vs Apr 1, 2022 | 105 | SEC filing |
| Apr 1, 2022 | Amendment | $7,660,000 | $2,620,000vs Apr 2, 2021 | 50 | SEC filing |
| Apr 2, 2021 | Amendment | $5,040,000 | -$13,175,000vs Jun 10, 2020 | 26 | SEC filing |
| Jun 10, 2020 | Amendment | $18,215,000 | $17,325,000vs Apr 8, 2020 | 17 | SEC filing |
| Apr 8, 2020 | Initial | $890,000 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06c
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $603K (estimated)
- Finders' fees
- $0
- Form D file number
- 021-364508
7% cash sales commission and 7% warrant coverage to be paid to any broker/dealer engaged.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Craft Capital Management LLC | 171350 | Craft Capital Management LLC · CRD 171350 |
Source: Form D, filed Apr 1, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Hojabr Alimi | Director, Executive, Promoter |
| David Allie | Director |
| Tchekanova Banafsheh | Executive |
| Ronald Carli | Director |
| Sameer Harish | Executive |
| Kate Lewis | Director |
| Steven Solferino | Director |
| Jerry Stonemetz | Executive |
| William H. Watson | Director, Executive, Promoter |
| William Henry Watson Iii | Director, Executive, Promoter |
| Richard Zimmer | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:Petaluma, CA, 94954
Phone: 707-668-7600